Irhythm Technologies [IRTC] vs Abbott Laboratories [ABT] Detailed Stock Comparison
Irhythm Technologies
NASDAQ
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Irhythm Technologies wins in 4 metrics, Abbott Laboratories wins in 14 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Irhythm Technologies | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -46.73 | 16.75 | Irhythm Technologies |
| Price-to-Book Ratio | 52.49 | 4.59 | Abbott Laboratories |
| Debt-to-Equity Ratio | 708.80 | 26.50 | Abbott Laboratories |
| PEG Ratio | 1.45 | 0.46 | Abbott Laboratories |
| EV/EBITDA | -118.79 | 20.85 | Irhythm Technologies |
| Profit Margin (TTM) | -14.06% | 32.43% | Abbott Laboratories |
| Operating Margin (TTM) | -5.71% | 19.73% | Abbott Laboratories |
| EBITDA Margin (TTM) | N/A | 19.73% | N/A |
| Return on Equity | -91.14% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | -3.53% | 6.62% | Abbott Laboratories |
| Free Cash Flow (TTM) | $-45.55M | $6.35B | Abbott Laboratories |
| Dividend Yield | N/A | 1.28% | N/A |
| 1-Year Return | 177.16% | 18.07% | Irhythm Technologies |
| Price-to-Sales Ratio (TTM) | 8.35 | 5.39 | Abbott Laboratories |
| Enterprise Value | $5.63B | $238.75B | Abbott Laboratories |
| EV/Revenue Ratio | 8.57 | 5.54 | Abbott Laboratories |
| Gross Profit Margin (TTM) | 71.17% | 56.44% | Irhythm Technologies |
| Revenue per Share (TTM) | $21 | $25 | Abbott Laboratories |
| Earnings per Share (Diluted) | $-2.90 | $7.97 | Abbott Laboratories |
| Beta (Stock Volatility) | 1.11 | 0.70 | Abbott Laboratories |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Irhythm Technologies vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Irhythm Technologies | 3.80% | 1.42% | 1.60% | 21.73% | 60.44% | 94.33% |
| Abbott Laboratories | -0.36% | -0.24% | 1.16% | -0.84% | 0.80% | 17.23% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Irhythm Technologies | 177.16% | 41.39% | -30.99% | 573.94% | 573.94% | 573.94% |
| Abbott Laboratories | 18.07% | 30.65% | 21.29% | 217.47% | 424.82% | 549.05% |
News Based Sentiment: Irhythm Technologies vs Abbott Laboratories
Irhythm Technologies
News based Sentiment: MIXED
iRhythm experienced a strong second quarter with revenue growth and increased analyst price targets, but this was offset by significant insider selling and ongoing financial concerns, including a high debt load and negative profitability. The mixed signals create a complex investment picture requiring careful consideration.
Abbott Laboratories
News based Sentiment: POSITIVE
Abbott Laboratories reported strong Q2 2025 earnings and raised its full-year guidance, leading to positive analyst upgrades and increased institutional investment. While the ongoing NEC litigation presents a risk, the overall narrative is positive, suggesting continued growth and profitability for the company.
Performance & Financial Health Analysis: Irhythm Technologies vs Abbott Laboratories
| Metric | IRTC | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $5.45B | $231.60B |
| Market Cap Category | Mid cap | Mega cap |
| 10 Day Avg. Volume | 395,770 | 6,299,450 |
| 90 Day Avg. Volume | 396,597 | 5,376,593 |
| Last Close | $173.81 | $132.99 |
| 52 Week Range | $55.92 - $187.57 | $110.86 - $141.23 |
| % from 52W High | -7.34% | -5.83% |
| All-Time High | $286.19 (Jan 25, 2021) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -39.27% | -6.74% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.26% | 0.07% |
| Quarterly Earnings Growth | 0.26% | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | -0.14% | 0.32% |
| Operating Margin (TTM) | -0.06% | 0.20% |
| Return on Equity (TTM) | -0.91% | 0.31% |
| Debt to Equity (MRQ) | 708.80 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $3.23 | $29.05 |
| Cash per Share (MRQ) | $16.98 | $4.18 |
| Operating Cash Flow (TTM) | $63.35M | $9.04B |
| Levered Free Cash Flow (TTM) | $47.56M | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.28% |
| Last 12-Month Dividend | N/A | $1.69 |
Valuation & Enterprise Metrics Analysis: Irhythm Technologies vs Abbott Laboratories
| Metric | IRTC | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -46.73 | 16.75 |
| Forward P/E | -92.12 | 25.87 |
| PEG Ratio | 1.45 | 0.46 |
| Price to Sales (TTM) | 8.35 | 5.39 |
| Price to Book (MRQ) | 52.49 | 4.59 |
| Market Capitalization | ||
| Market Capitalization | $5.45B | $231.60B |
| Enterprise Value | $5.63B | $238.75B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 8.57 | 5.54 |
| Enterprise to EBITDA | -118.79 | 20.85 |
| Risk & Other Metrics | ||
| Beta | 1.11 | 0.70 |
| Book Value per Share (MRQ) | $3.23 | $29.05 |
Financial Statements Comparison: Irhythm Technologies vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IRTC | ABT |
|---|---|---|
| Revenue/Sales | $158.68M | $10.36B |
| Cost of Goods Sold | $49.46M | $4.47B |
| Gross Profit | $109.22M | $5.89B |
| Research & Development | $21.82M | $716.00M |
| Operating Income (EBIT) | $-32.56M | $1.69B |
| EBITDA | $-20.95M | $2.66B |
| Pre-Tax Income | $-30.04M | $1.78B |
| Income Tax | $665,000 | $453.00M |
| Net Income (Profit) | $-30.70M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IRTC | ABT |
|---|---|---|
| Cash & Equivalents | $375.28M | $6.53B |
| Total Current Assets | $636.01M | $23.15B |
| Total Current Liabilities | $111.34M | $13.00B |
| Long-Term Debt | $719.36M | $12.74B |
| Total Shareholders Equity | $86.67M | $49.06B |
| Retained Earnings | $-789.60M | $47.72B |
| Property, Plant & Equipment | $55.71M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IRTC | ABT |
|---|---|---|
| Operating Cash Flow | $-31.20M | $1.42B |
| Capital Expenditures | $-9.42M | $-484.00M |
| Free Cash Flow | $-17.31M | $933.00M |
| Debt Repayment | $0 | $-1.00B |
| Common Stock Repurchase | $0 | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | IRTC | ABT |
|---|---|---|
| Shares Short | 2.66M | 18.07M |
| Short Ratio | 6.69 | 3.68 |
| Short % of Float | 0.09% | 0.01% |
| Average Daily Volume (10 Day) | 395,770 | 6,299,450 |
| Average Daily Volume (90 Day) | 396,597 | 5,376,593 |
| Shares Outstanding | 31.39M | 1.73B |
| Float Shares | 31.75M | 1.73B |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 1.17% | 0.81% |
Dividend Analysis & Yield Comparison: Irhythm Technologies vs Abbott Laboratories
| Metric | IRTC | ABT |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.69 |
| Last 12-Month Dividend Yield | N/A | 1.28% |
| 3-Year Avg Annual Dividend | N/A | $1.92 |
| 3-Year Avg Dividend Yield | N/A | 0.49% |
| 3-Year Total Dividends | N/A | $5.77 |
| Ex-Dividend Date | N/A | Jan 15, 2025 |